Abstract 280P
Background
Multiple studies in the past have elaborated the role of different risks stratification scores such as Sokal, Hasford, and Eutos (S.H.E.). These studies either correlated the risk stratification with survival, PFS, CcyR, MMR, or point BCR-ABL at different time intervals post-TKI. However, as we understand, all patients do not have a similar disease burden at the initiation of TKI. Also, using cut off level for different age group, gender, and disease burdens is an oversimplification of the disease remission criteria. There are very few studies on the rate (velocity) of the fall of BCR-ABL. The aim of this study was to compare the efficacy of various prognostic score in predicting the fall in BCR ABL over two years.
Methods
This is a prospective observational study comprising 653 (sample size predicted: 300) patients managed at a tertiary care center in north India based on a uniform treatment and evaluation protocol (Generic Imatinib 400 mg OD and three monthly RQ-PCR-BCR/ABL-IS). Statistics were done using Python-13.
Results
The median age of the study population was 43 years (16-87). On comparing the three risk groups of Sokal, the high-risk patients had the least fall in BCR-ABL at any time point up to 2 years post intiation of TKI. Whereas, there was no difference between low and intermediate risk. The difference in the three groups was not statistically significant. There was also no statistically significant difference in the rate of fall of BCR/ABL in the three risk groups of Hasford. The two risk groups of Eutos score had a significant difference in the rate of fall of BCR/ABL, the high risk having a lower rate in comparison to low risk.
Conclusions
Of the three scoring systems, the EUTOS score outperforms as a prognostic model using rate of fall of BCR-ABL in newly diagnosed CML-CP patients upto two years on Generic Imatinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NA.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract